# A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

> **NCT06308978** · PHASE1 · RECRUITING · sponsor: **Fate Therapeutics** · enrollment: 244 (estimated)

## Conditions studied

- Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)
- Idiopathic Inflammatory Myositis (IIM)
- Systemic Sclerosis (SSc)
- Systemic Lupus Erythematosus (SLE)
- Lupus Nephritis

## Interventions

- **DRUG:** FT819
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT06308978
- **Lead sponsor:** Fate Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-28
- **Primary completion:** 2027-09-30
- **Final completion:** 2042-09-30
- **Target enrollment:** 244 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06308978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06308978, "A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06308978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*